{"id":"W2556710404","doi":"10.1182/blood.v118.21.813.813","title":"Final Results From the Bortezomib-naive Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Bortezomib; Tolerability; Medicine; Multiple myeloma; Regimen; Refractory (planetary science); Proteasome inhibitor; Internal medicine; Clinical endpoint; Oncology; Cohort; Progression-free survival; Surgery; Adverse effect; Overall survival; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008128168,0.001910308,0.002411791,0.0007435533,0.00067283,0.001116495,0.001132091,0.001226311,0.003792528],"category_scores_gemma":[0.003177511,0.000761324,0.001664482,0.0006320905,0.0003694112,0.0006591222,0.0005476525,0.002544189,0.0008845693],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009146198,"about_ca_system_score_gemma":0.00159089,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001440656,"about_ca_topic_score_gemma":0.002413904,"domain_scores_codex":[0.9981646,0.0009873662,0.000161399,0.0001529679,0.0003296543,0.0002041494],"domain_scores_gemma":[0.9974846,0.0006500211,0.0004834044,0.0002344461,0.0004274976,0.0007200541],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6592542,0.02321859,0.02682451,0.001589131,0.006231298,0.0007444274,0.0005621349,0.004569863,0.05827576,0.000280842,0.05277224,0.165677],"study_design_scores_gemma":[0.3384654,0.4472459,0.1582859,0.0001572373,0.004311889,0.0008474935,0.00008722067,0.001795038,0.01780579,0.0003043897,0.0305615,0.0001323796],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9255602,0.01028289,0.003272426,0.001960688,0.0004816962,0.01234971,0.03384987,0.0005015579,0.01174086],"genre_scores_gemma":[0.8756776,0.004170506,0.007781591,0.002430252,0.0006936311,0.008463569,0.08812892,0.0002491387,0.01240476],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008128168,"threshold_uncertainty_score":0.04298639,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06477484060319613,"score_gpt":0.2906286943244425,"score_spread":0.2258538537212464,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}